Patents - Global Data - Dimensions
RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
Applicants:
- Bavarian Nordic (Denmark) [NORA names: Bavarian Nordic; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.
Patent Family Records (1)
RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
BAVARIAN NORDIC AS, Bavarian Nordic (Denmark) STEIGERWALD ROBIN, MEDINA ECHEVERZ JOSÉ, HEISEKE ALEXANDER, (...more)
2024, WO-2024003239-A1
